Tech Company Financing Transactions
Conatus Pharmaceuticals Funding Round
On 5/11/2007, Conatus Pharmaceuticals raised $22 million in Series A funding from Aberdare Ventures, Advent International and Bay City Capital.
Transaction Overview
Company Name
Announced On
5/11/2007
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Proceeds Purpose
The proceeds will be used for multiple Phase 2 studies in patients with liver disease. The drug will be initially evaluated in patients infected with the Hepatitis C virus (HCV) who have failed existing treatments (refractory to the standard of care) and is scheduled to begin at the end of 2007. Conatus licensed in CTS-1027 from F. Hoffmann-La Roche Ltd in November 2006.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
16745 West Bernardo Dr. 200
San Diego, CA 92127
USA
San Diego, CA 92127
USA
Phone
Website
Email Address
Overview
Conatus Pharmaceuticals is focused on the development of human therapeutics to treat liver failures and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Mento
Chief Operating Officer
Keith Marshall
VP - Finance
Michelle Vandertie
VP - R & D
Alfred Spada
Browse more venture capital transactions:
Prev: 5/11/2007: Turin Networks venture capital transaction
Next: 5/14/2007: ScanScout venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs